Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Towards selectively modulating mineralocorticoid receptor function: lessons from other systems.

John D Baxter1, John W Funder, James W Apriletti

  • 1Diabetes Center and Metabolic Research Unit, University of California-San Francisco, San Francisco, CA 94143-0540, USA. jbaxter918@aol.com

Molecular and Cellular Endocrinology
|May 12, 2004
PubMed
Summary

Developing novel mineralocorticoid receptor (MR) antagonists is crucial due to limitations of current drugs. Research explores selective thyroid receptor (TR) modulators to inform the design of more specific MR-targeting compounds.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Structure-Based Discovery of Potent BCL-XL Inhibitors through Rescaffolding.

Journal of medicinal chemistry·2026
Same author

Editorial: Understanding effective education: far transfer from a sociocultural and cognitive neural perspective.

Frontiers in psychology·2026
Same author

HIV-1 Drug Resistance Trends in the Era of Modern Antiretrovirals: 2018-2024.

Open forum infectious diseases·2025
Same author

Rhythmic high-amplitude delta with superimposed spikes (RHADS): a treatment dilemma.

Oxford medical case reports·2024
Same author

Complete genome sequences of sucrose non-fermenting non-O1/non-O139 <i>Vibrio cholerae</i> isolated from human soft tissue infection.

Microbiology resource announcements·2024
Same author

Comparing ARR Versus Suppressed PRA as Screening Tests for Primary Aldosteronism.

Hypertension (Dallas, Tex. : 1979)·2024

Area of Science:

  • Endocrinology and Pharmacology
  • Molecular Biology
  • Drug Discovery

Background:

  • Current mineralocorticoid receptor (MR) antagonists like spironolactone and eplerenone have limitations including cross-reactivity and low affinity.
  • MR binds both aldosterone and cortisol, which can act as agonists or antagonists depending on the tissue context.
  • There is a need for MR antagonists with improved selectivity, potency, and the ability to induce specific receptor conformations.

Purpose of the Study:

  • To explore novel strategies for designing improved MR antagonists.
  • To investigate the potential of applying insights from selective thyroid receptor (TR) modulator development to MR ligand design.
  • To identify compounds that offer higher specificity and potential tissue-specific modulation of MR action.

Main Methods:

Related Experiment Videos

  • Utilized traditional medicinal chemistry approaches.
  • Employed X-ray crystallography to guide the design of selective ligands.
  • Focused on developing selective modulators for the thyroid receptor (TR) as a model system.

Main Results:

  • Successfully obtained several classes of selective TR modulators.
  • Characterized the properties of these selective TR modulators.
  • The study provides a framework for designing novel MR modulators.

Conclusions:

  • Insights gained from developing selective TR modulators can inform the design of novel MR-interacting compounds.
  • Future MR antagonists could achieve improved specificity and potentially tissue-specific effects.
  • This approach holds promise for developing more effective therapies targeting the MR pathway.